Survival Analysis of 81 Cases of EB Virus-Associated Hemophagocytic Syndrome

Background To examine the clinical features and laboratory results of EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) and identify risk factors influencing survival outcomes in pediatric patients. Methods Retrospective analysis of the clinical data and laboratory examination of 81 patients with EBV-HLH admitted to the Children's Hospital of Soochow University from January 2019 to November 2024. Stepwise regression and multivariate Cox regression were employed to identify prognostic factors, and Kaplan-Meier methods were used for survival analysis. Results 1. RPR and CREA serve as prognostic predictors for EBV-HLH patients, with area under the curve (AUC) values of 0.805 and 0.727, respectively. Cutoff values of 0.246 and 41.45 µmol/L yielded sensitivities of 0.917 and 0.583, and specificities of 0.638 and 0.884, respectively. 2. Survival analysis revealed that patients with RPR ≥ 0.246 mmol/L and CREA ≥ 41.45 µmol/L had significantly lower survival rates than those with RPR ≤ 0.246 mmol/L and CREA ≤ 41.45 µmol/L. Conclusion RPR and CREA serve as indicators for clinical decision-making in EBV-HLH patients, facilitating early intervention and improving patient outcomes.